| Name |
Aflibercept (USAN/INN);Aflibercept (genetical recombination) (JAN);Aflibercept (genetical recombination) [Aflibercept biosimilar 1] (JAN);Ziv-aflibercept;Aflibercept-mrbb;Eylea (TN);Zaltrap (TN);Ahzantive (TN) |
| Product |
AHZANTIVE (Valorum Biologics), EYLEA (Regeneron Pharmaceuticals), EYLEA HD (Regeneron Pharmaceuticals), PAVBLU (Amgen), ZALTRAP (sanofi-aventis U.S. LLC) |
| Formula |
C4318H6788N1164O1304S32 |
| Exact mass |
96837.1694 |
| Mol weight |
96897.26 |
| Sequence |
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDSRKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKLVLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQGLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISRTPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLNGKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPSDIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNHYTQKSLSLSP G(Disulfide bridge: 30-79, 124-185, 246-306, 352-410, 211-211', 214-214') |
| Type |
Peptide |
| Remark |
Therapeutic category: 1319ATC code: L01XX44 S01LA05Product: D09574<JP/US> |
| Efficacy |
Angiogenesis inhibitor |
| Disease |
Age-related macular degeneration [DS:H00821]Macular edema [DS:H01651]Diabetic macular edema [DS:H01651]Diabetic retinopathy [DS:H01457]Colorectal cancer [DS:H00020] |
| Comment |
fusion proteinVEGF-TrapInhibitor of aberrant angiogenesis-vascular leak and inflammation, angiogenesis inhibitor for treatment of cancer |
| Target |
VEGFA [HSA:7422] [KO:K05448]VEGFB [HSA:7423] [KO:K16858]PGF [HSA:5228] [KO:K16859] |
| Pathway |
hsa04370 VEGF signaling pathwayhsa05200 Pathways in cancer |
| Interaction |
|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01X OTHER ANTINEOPLASTIC AGENTS L01XX Other antineoplastic agents L01XX44 Aflibercept D09574 Aflibercept (USAN/INN) <JP/US> S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01L OCULAR VASCULAR DISORDER AGENTS S01LA Antineovascularisation agents S01LA05 Aflibercept D09574 Aflibercept (USAN/INN) <JP/US>USP drug classification [BR:br08302] Antineoplastics Antineoplastics, Other Antineoplastics, Miscellaneous Ziv-aflibercept D09574 Aflibercept (USAN/INN) Ophthalmic Agents Ophthalmic Agents, Other Aflibercept D09574 Aflibercept (USAN/INN)Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 13 Agents affecting sensory organs 131 Ophthalmic agents 1319 Others D09574 Aflibercept (USAN/INN); Aflibercept (genetical recombination) (JAN); Aflibercept (genetical recombination) [Aflibercept biosimilar 1] (JAN)Target-based classification of drugs [BR:br08310] Cytokines and receptors Cytokines Growth factors (RTK-binding) PGF D09574 Aflibercept (USAN/INN) <JP/US> VEGFA D09574 Aflibercept (USAN/INN) <JP/US> VEGFB D09574 Aflibercept (USAN/INN) <JP/US>New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D09574New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D09574New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09574New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09574 |
| Other DBs |
CAS: 862111-32-8PubChem: 124490314 |
| LinkDB |
|